Literature DB >> 23981102

Diagnosis, pathogenesis and treatment of myositis: recent advances.

P-O Carstens1, J Schmidt.   

Abstract

Dermatomyositis (DM), polymyositis (PM), necrotizing myopathy (NM) and inclusion body myositis (IBM) are four distinct subtypes of idiopathic inflammatory myopathies - in short myositis. Recent studies have shed some light on the unique pathogenesis of each entity. Some of the clinical features are distinct, but muscle biopsy is indispensable for making a reliable diagnosis. The use of magnetic resonance imaging of skeletal muscles and detection of myositis-specific autoantibodies have become useful additions to our diagnostic repertoire. Only few controlled trials are available to substantiate current treatment approaches for myositis and hopes are high that novel modalities will become available within the next few years. In this review we provide an up-to-date overview of the pathogenesis and diagnostic approach of myositis. We aim to present a guide towards therapeutic and general management.
© 2013 British Society for Immunology.

Entities:  

Keywords:  muscle immunology/disease; myositis; neuroimmunology

Mesh:

Year:  2014        PMID: 23981102      PMCID: PMC3927896          DOI: 10.1111/cei.12194

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  109 in total

1.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

2.  Necrotizing myopathy: clinicoserologic associations.

Authors:  Elizabeth Ellis; Ju Ann Tan; Sue Lester; Graeme Tucker; Peter Blumbergs; Peter Roberts-Thomson; Vidya Limaye
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

Review 3.  A rheumatologist's view of polymyositis/dermatomyositis: extracutaneous and extramuscular involvement and overlap syndromes.

Authors:  B Romans; S Cohen
Journal:  Clin Dermatol       Date:  1988 Apr-Jun       Impact factor: 3.541

Review 4.  Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson; Ingrid E Lundberg
Journal:  Curr Opin Rheumatol       Date:  2012-03       Impact factor: 5.006

5.  A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.

Authors:  Fieke M Cox; Maarten J Titulaer; Jacob K Sont; Axel R Wintzen; Jan J G M Verschuuren; Umesh A Badrising
Journal:  Brain       Date:  2011-09-09       Impact factor: 13.501

6.  Oropharyngeal dysphagia in polymyositis/dermatomyositis.

Authors:  Cumhur Ertekin; Yaprak Seçil; Nur Yüceyar; Ibrahim Aydoğdu
Journal:  Clin Neurol Neurosurg       Date:  2004-12       Impact factor: 1.876

7.  Long-term observational study of sporadic inclusion body myositis.

Authors:  Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal:  Brain       Date:  2011-10-12       Impact factor: 13.501

Review 8.  Overlap connective tissue disease syndromes.

Authors:  Luca Iaccarino; Mariele Gatto; Silvano Bettio; Francesco Caso; Mariaelisa Rampudda; Margherita Zen; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Autoimmun Rev       Date:  2012-06-26       Impact factor: 9.754

9.  Immunopathologic study of skin lesions in dermatomyositis.

Authors:  G Hausmann; C Herrero; M C Cid; J Casademont; M Lecha; J M Mascaró
Journal:  J Am Acad Dermatol       Date:  1991-08       Impact factor: 11.527

10.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ana Patrícia Paula; Cristiano Zerbini; Diogo S Domiciano; Helenice Gonçalves; Jaime S Danowski; João F Marques Neto; Laura M C Mendonça; Mailze C Bezerra; Maria Teresa Terreri; Marta Imamura; Pedro Weingrill; Perola G Plapler; Sebastião Radominski; Tatiana Tourinho; Vera L Szejnfeld; Nathalia C Andrada
Journal:  Rev Bras Reumatol       Date:  2012-08
View more
  30 in total

1.  Neuroinflammation of the central and peripheral nervous system: an update.

Authors:  O Stüve; U Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

2.  Transient quadriceps paresis following cocaine use.

Authors:  George A Demetriou
Journal:  BMJ Case Rep       Date:  2014-01-06

3.  Antibodies to watch in 2014.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2013-11-25       Impact factor: 5.857

Review 4.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Juvenile dermatomyositis: a tertiary center experience.

Authors:  Kenan Barut; Pinar Ozge Avar Aydin; Amra Adrovic; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

6.  Role of bone scan in the assessment of polymyositis/dermatomyositis.

Authors:  Young-Sil An; Chang-Hee Suh; Ju-Yang Jung; Hyoun-Ah Kim
Journal:  Clin Rheumatol       Date:  2014-12-12       Impact factor: 2.980

Review 7.  [Dermatomyositis-update].

Authors:  B Volc-Platzer
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 8.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 9.  Abatacept as a successful therapy for myositis—a case-based review.

Authors:  Anne M Kerola; Markku J Kauppi
Journal:  Clin Rheumatol       Date:  2014-02-04       Impact factor: 2.980

Review 10.  Idiopathic inflammatory myopathies - a guide to subtypes, diagnostic approach and treatment.

Authors:  Alexander Oldroyd; James Lilleker; Hector Chinoy
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.